CORRECTION Alnylam Pharmaceuticals Q4 2023 Adj EPS $(0.77) Beats $(1.32) Estimate, Sales $439.72M Miss $442.90M Estimate
Portfolio Pulse from Benzinga Newsdesk
Alnylam Pharmaceuticals reported its Q4 2023 adjusted EPS at $(0.77), surpassing the $(1.32) estimate. However, its sales of $439.72M fell short of the expected $442.90M.
February 15, 2024 | 5:04 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Alnylam Pharmaceuticals exceeded Q4 2023 EPS estimates but missed sales forecasts.
The mixed results with an EPS beat and a slight miss on sales forecasts could lead to a neutral short-term impact on ALNY's stock price. Investors may view the earnings beat positively, but the sales miss could temper optimism.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100